跳至主要内容
临床试验/JPRN-jRCT2032220027
JPRN-jRCT2032220027招募中未知

A clinical study of the ultrasonic renal denervation system (PRDS-001) in patients with hypertension - RADIANCE-HTN DUO

Kai Hisashi0 个研究点目标入组 154 人开始时间: 2022年4月16日最近更新:
适应症

试验速览

阶段
未知
状态
招募中
发起方
入组人数
154

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
>= 20age old 至 <= 75age old(—)
性别
All

入选标准

  • 1. Patients who have received antihypertensive treatment with two antihypertensive drugs for at least 4 weeks prior to obtaining consent, with no change in the type or dosage
  • 2. Patients with a mean seated office blood pressure of between 140 mmHg and 180 mmHg systolic and between 90 mmHg and 110 mmHg diastolic at screening visit
  • 3. Patients with a mean 24-hour ABPM (ambulatory blood pressure measurement) of between 130 mmHg and 170 mmHg systolic and between 80 mmHg and 105 mmHg diastolic at baseline visit

排除标准

  • 1. Lacks appropriate renal artery anatomy for renal denervation
  • 2. Secondary hypertension other than sleep apnea
  • 3. Type 1 diabetes mellitus or uncontrolled Type 2 diabetes
  • 4. Any history of cerebrovascular event or severe cardiovascular event, within 6 months prior to consent
  • 5. Repeated hospitalization for hypertensive crisis (twice or more) within 12 months prior to obtaining consent, or any hospitalization for hypertensive crisis within 3 months prior to obtaining consent
  • 6. Patients prescribed to drugs that have antihypertensive effects for other chronic diseases, and the investigator considers that discontinuation of these drugs may pose a serious risk to health
  • 7. Patients who are taking drugs known to affect blood pressure and the investigator judges that it is not possible to discontinue these drugs during the study period
  • 8. Patients with a history of persistent or permanent atrial tachyarrhythmia
  • 9. Patients with active implantable medical devices
  • 10. Primary pulmonary hypertension
  • 11. Patients with contraindications or unacceptable anaphylactic reactions or uncontrolled allergy to contrast media
  • 12. Night shift workers
  • 13. Pregnant, nursing or planning to become pregnant
  • 14. Patients with COVID-19 infection within 3 months prior to obtaining consent
  • 15. Patients with any of the following central laboratory tests at screening
  • - Plasma aldosterone/renin ratio greater than or equal to 200 or plasma aldosterone greater than or equal to 60 pg/ml
  • - HbA1c greater than or equal to 8.0%
  • - eGFR less than 40 mL/min/1.73m^2

研究者

发起方
Kai Hisashi

相似试验